ABEO — ABEONA THERAPEUTICS INC.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 318306 ·
Last close
$6.06
Market Cap
$346.54M
52W High
$7.65
52W Low
$5.24
ADV30
1,466,979
Next earnings
2026-11-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 8,720,000 | 6,024,000 | -23,033,000 | -17,075,000 | 198,494,000 | 61,374,000 | 53,555,000 |
| Dec 2025 | 5,420,000 | 2,583,000 | -22,911,000 | -20,460,000 | 219,570,000 | 78,437,000 | 60,354,000 |
| Sep 2025 | 0 | -488,000 | -24,018,000 | -5,161,000 | 231,095,000 | 82,884,000 | 59,862,000 |
| Jun 2025 | 400,000 | 300,000 | -22,792,000 | 108,833,000 | 246,233,000 | 163,535,000 | 82,657,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-77,728,000
Investing CF
$105,778,000
Financing CF
$17,050,000
CapEx
$-7,509,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$1.07
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-759,150,000
Inventory
$6,054,000
Receivables
$6,709,000
ST Investments
$106,897,000
EBIT TTM
$69,811,000
Pretax Income TTM
$66,239,000
Interest Exp TTM
$3,572,000
Analysts
7
Yahoo Snapshot (yfinance, live)
Total Revenue
$25,520,000
EBITDA
$-80,789,000
Free Cash Flow
$-73,398,752
Enterprise Value
$221,296,656
Total Cash
$146,826,000
Total Debt
$19,872,000
Shares Out
57,184,017
Trailing EPS
$-1.21
Book Value
$2.24
ROE
-43.1%
ROA
-24.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 5,820,000 | -89,448,000 | 71,183,000 | 219,570,000 | 60,354,000 | — | -76,326,000 |
| Dec 2024 | 0 | -64,211,000 | -63,734,000 | 108,931,000 | 64,900,000 | — | -56,015,000 |
| Dec 2023 | 3,500,000 | -48,200,000 | -54,188,000 | 64,002,000 | 49,176,000 | — | -37,009,000 |
| Dec 2022 | 1,414,000 | -45,257,000 | -39,696,000 | 64,214,000 | 37,453,000 | — | -43,483,000 |
TTM Snapshot
Revenues TTM
$2,309,000
NetIncome TTM
$-15,533,000
OpCashFlow TTM
$0
Assets (Latest)
$16,582,000
Forward EPS
$-0.18
Max Pain — expiry 2026-09-18
max pain strike: $5.00 · spot: $6.06 · call oi: 4,481 · put oi: 1,869
Expected Move to 2026-09-18:
±$0.75
(12.38%) —
implied range
$5.31 –
$6.81
· ATM straddle on $6.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PRQR | ProQR Therapeutics N.V. | $342.92M | $2.43 | — |
| DMAC | DiaMedica Therapeutics Inc. | $351.60M | $6.52 | — |
| ZNTL | Zentalis Pharmaceuticals, Inc. | $355.97M | $3.76 | — |
| IRD | Opus Genetics, Inc. | $335.28M | $4.03 | — |
| IMRX | Immuneering Corp | $335.13M | $5.18 | — |
News headlines (Yahoo Finance, 1h cache)
Abeona Therapeutics Inc (ABEO) (Q2 2026) Earnings Call Highlights: ZEVASKYN Revenue Surges 31% ...
2026-08-17 19:03 · Yahoo
ABEO: Zevaskyn® Launch Gains Momentum
2026-08-17 15:05 · Yahoo
Abeona Therapeutics® Reports Second Quarter 2026 Results and Provides Business Update
2026-08-13 11:30 · Yahoo
Abeona Therapeutics® to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026
2026-08-06 11:30 · Yahoo
Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®
2026-07-21 11:30 · Yahoo
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-01 11:30 · Yahoo
CMS Grants New Technology Add-On Payment (NTAP) Status for ZEVASKYN®
2026-08-04 11:30 · Yahoo
Abeona’s (ABEO) Gene Therapy Launch Hits A Pivotal Reimbursement Milestone
2026-08-21 15:42 · Yahoo
Abeona Therapeutics Inc. Q2 2026 Earnings Call Summary
2026-08-13 20:56 · Yahoo
Abeona Therapeutics Q2 Earnings Call Highlights
2026-08-13 14:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.